PDUFA date set for pirfenidone NDA

The FDA acknowledges the receipt of Intermune's (ITMN) resubmitted NDA for pirfenidone. The PDUFA date in November 23, 2014. The agency sent the company a CRL in May 2010 recommending an additional Phase 3 clinical trial to support the efficacy of the product. Pirfenidone is being developed as a treatment for idiopathic pulmonary fibrosis in adult patients.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs